Investing.com - Immix Biopharma (NASDAQ: IMMX) reported third quarter EPS of $-0.23, in line with the analyst estimate of $-0.23. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.00.
Immix Biopharma's stock price closed at $5.08. It is up 121.83% in the last 3 months and up 337.97% in the last 12 months.
Immix Biopharma saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Immix Biopharma's stock price’s past reactions to earnings here.
According to InvestingPro, Immix Biopharma's Financial Health score is "good performance".
Check out Immix Biopharma's recent earnings performance, and Immix Biopharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar